Using Real World Evidence to Guide Treatment Decisions in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan presents a clinical case scenario to explore how real world evidence informs treatment decisions in metastatic castration sensitive prostate cancer (mCSPC). Although the discussion moves slightly beyond the original discussion guide, the conversation remains focused on how clinicians apply real world insights when selecting and managing therapy. Dr. Alan H. Bryce, along with the panel, discusses how patient characteristics such as age, comorbidities, functional status, and medication burden can influence treatment choice and long term management. The case based discussion highlights how physicians integrate evidence from clinical trials with real world experience to determine the most appropriate treatment strategy for individual patients. The panel also reflects on how treatment persistence, tolerability, and patient preferences can affect therapy selection and long term outcomes. Overall, this segment illustrates how real world evidence and clinical judgment together guide personalized care in metastatic castration sensitive prostate cancer.